Page last updated: December 13, 2018

Keynote 629

For patients with recurrent or metastatic or locally advanced cutaneous squamous cell carcinoma

Study of Pembrolizumab in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma or Locally Advanced Unresectable cSCC

The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) in adult participants with recurrent or metastatic(R/M) cutaneous Squamous Cell Carcinoma (cSCC) or locally advanced (LA) unresectable cSCC that is not amenable to surgery and/or radiation and/or systemic therapies.

Status:

Recruiting

Phase 2 Icon

Trial Phase

The investigational immunotherapy is being studied in a group of patients to see if it is safe and effective.

Eligibility

About the Trial

All patients who enroll in the trial will receive medication while on the study.

  • 100% will receive pembrolizumab only


Trial Purpose
14

US Trial Locations

Clinical trial sites are places such as hospitals or clinics where the trial is being conducted.

See Locations

National Trial Reference Number

NCT03284424 Read More at clinicaltrials.gov
I’m interested in this trial

What Can You Do Next?

If you would like to learn about this clinical trial or see if you can participate, you can:

Contact Our Trial Info Center

To learn more, call 1-888-577-8839

Discuss With Your Doctor

Print this page or Email it to your doctor to discuss at your next visit

Stay Informed

Sign up to receive email alerts about this trial or when a location becomes available

Back to trial information
Tip: To help with understanding of some clinical terms used on the page, select an underlined term to see what they mean.

Eligibility

Only a qualified healthcare professional can determine your eligibility. However, this information may be useful in starting a conversation with your doctor.

Condition

The disease, disorder, syndrome, illness, or injury that is being studied. Conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.
Squamous Cell Carcinoma

Age range

18 — no age maximum

Gender(s)

All

Trial Purpose

The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) in adult participants with recurrent or metastatic(R/M) cutaneous Squamous Cell Carcinoma (cSCC) or locally advanced (LA) unresectable cSCC that is not amenable to surgery and/or radiation and/or systemic therapies.

Important information

Participating in a clinical trial is an important decision. Anyone participating in a trial should know as much as possible about what is being studied, what risks are involved and what potential benefits may be gained before deciding to enroll. If you are interested in participating in a clinical trial, please talk to your doctor first.

Trial Locations

Sign up to receive an email alert when a clinical trial location in your area begins accepting patients.

    Location
    Status
  • Tulsa, Oklahoma, United States, 74146
    Recruiting
  • Sioux Falls, South Dakota, United States, 57104
    Recruiting
  • Dallas, Texas, United States, 75246
    Recruiting
  • Indianapolis, Indiana, United States, 46202
    Recruiting
  • Santa Rosa, California, United States, 95403
    Recruiting
  • Washington, District of Columbia, United States, 20007
    Recruiting
  • New Haven, Connecticut, United States, 06520
    Recruiting
  • Boston, Massachusetts, United States, 02114
    Recruiting
  • Hackensack, New Jersey, United States, 07601
    Recruiting
  • Philadelphia, Pennsylvania, United States, 19111
    Recruiting
  • Palo Alto, California, United States, 94304
    Recruiting
  • Las Vegas, Nevada, United States, 89148
    Recruiting
  • Westwood, Kansas, United States, 66205
    Recruiting
  • La Jolla, California, United States, 92093-0880
    Recruiting

How to Learn More

When speaking to your doctor, please have the trial reference number available. You can also call 1-888-577-8839 for more information.

Print or email this page.

Trial reference number

A unique identification code given to each clinical trial registered on clinicaltrials.gov.
NCT03284424

Keynote number

A unique identification code used by the sponsor to identify a specific trial.
Keynote-629

Official title

A description of the clinical trial that the trial sponsor and clinicians use to identify a specific trial and its purpose.
A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)
keynote 629 trial logo

Call 1-888-577-8839 to contact our trial information center

Keep me informed Learn more at clinicaltrials.gov

Clinical Trials: Important Information to Consider

There is a lot to consider when deciding whether to participate in a clinical study. Any clinical study includes risks, which the study doctor will review with you. Make sure you understand the risks before participating.